vs
MIMEDX GROUP, INC.（MDXG）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
MIMEDX GROUP, INC.的季度营收约是RE/MAX Holdings, Inc.的1.7倍（$118.1M vs $71.1M），MIMEDX GROUP, INC.净利率更高（12.9% vs 2.0%，领先10.8%），MIMEDX GROUP, INC.同比增速更快（27.1% vs -1.8%），过去两年MIMEDX GROUP, INC.的营收复合增速更高（18.1% vs -4.7%）
MiMedx是一家总部位于美国佐治亚州玛丽埃塔的生物医疗企业，成立于2008年。该企业以胎盘、羊膜囊、脐带等分娩组织为原料，开发可用于植皮手术的医用真皮产品，在生物再生医疗领域开展业务。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
MDXG vs RMAX — 直观对比
营收规模更大
MDXG
是对方的1.7倍
$71.1M
营收增速更快
MDXG
高出28.9%
-1.8%
净利率更高
MDXG
高出10.8%
2.0%
两年增速更快
MDXG
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.1M | $71.1M |
| 净利润 | $15.2M | $1.4M |
| 毛利率 | 83.9% | — |
| 营业利润率 | 17.8% | 13.1% |
| 净利率 | 12.9% | 2.0% |
| 营收同比 | 27.1% | -1.8% |
| 净利润同比 | 104.2% | -75.2% |
| 每股收益（稀释后） | $0.10 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDXGRMAX
| Q4 25 | $118.1M | $71.1M | ||
| Q3 25 | $113.7M | $73.2M | ||
| Q2 25 | $98.6M | $72.8M | ||
| Q1 25 | $88.2M | $74.5M | ||
| Q4 24 | $92.9M | $72.5M | ||
| Q3 24 | $84.1M | $78.5M | ||
| Q2 24 | $87.2M | $78.5M | ||
| Q1 24 | $84.7M | $78.3M |
净利润MDXGRMAX
| Q4 25 | $15.2M | $1.4M | ||
| Q3 25 | $16.7M | $4.0M | ||
| Q2 25 | $9.6M | $4.7M | ||
| Q1 25 | $7.0M | $-2.0M | ||
| Q4 24 | $7.4M | $5.8M | ||
| Q3 24 | $8.1M | $966.0K | ||
| Q2 24 | $17.6M | $3.7M | ||
| Q1 24 | $9.3M | $-3.4M |
毛利率MDXGRMAX
| Q4 25 | 83.9% | — | ||
| Q3 25 | 83.5% | — | ||
| Q2 25 | 81.1% | — | ||
| Q1 25 | 81.2% | — | ||
| Q4 24 | 81.8% | — | ||
| Q3 24 | 81.8% | — | ||
| Q2 24 | 83.0% | — | ||
| Q1 24 | 84.7% | — |
营业利润率MDXGRMAX
| Q4 25 | 17.8% | 13.1% | ||
| Q3 25 | 19.5% | 25.0% | ||
| Q2 25 | 12.5% | 19.3% | ||
| Q1 25 | 9.4% | 7.2% | ||
| Q4 24 | 11.9% | 5.9% | ||
| Q3 24 | 13.3% | 19.4% | ||
| Q2 24 | 26.9% | 20.6% | ||
| Q1 24 | 15.6% | 5.8% |
净利率MDXGRMAX
| Q4 25 | 12.9% | 2.0% | ||
| Q3 25 | 14.7% | 5.4% | ||
| Q2 25 | 9.8% | 6.4% | ||
| Q1 25 | 8.0% | -2.6% | ||
| Q4 24 | 8.0% | 8.0% | ||
| Q3 24 | 9.6% | 1.2% | ||
| Q2 24 | 20.2% | 4.7% | ||
| Q1 24 | 10.9% | -4.3% |
每股收益（稀释后）MDXGRMAX
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.11 | — | ||
| Q2 25 | $0.06 | — | ||
| Q1 25 | $0.05 | — | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $0.05 | — | ||
| Q2 24 | $0.12 | — | ||
| Q1 24 | $0.06 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $166.1M | $118.7M |
| 总债务越低越好 | $18.0M | $432.2M |
| 股东权益账面价值 | $256.5M | $452.4M |
| 总资产 | $342.7M | $582.5M |
| 负债/权益比越低杠杆越低 | 0.07× | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资MDXGRMAX
| Q4 25 | $166.1M | $118.7M | ||
| Q3 25 | $142.1M | $107.5M | ||
| Q2 25 | $118.9M | $94.3M | ||
| Q1 25 | $106.4M | $89.1M | ||
| Q4 24 | $104.4M | $96.6M | ||
| Q3 24 | $88.8M | $83.8M | ||
| Q2 24 | $69.0M | $66.1M | ||
| Q1 24 | $48.5M | $82.1M |
总债务MDXGRMAX
| Q4 25 | $18.0M | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | $19.0M | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益MDXGRMAX
| Q4 25 | $256.5M | $452.4M | ||
| Q3 25 | $238.9M | $448.1M | ||
| Q2 25 | $216.6M | $442.4M | ||
| Q1 25 | $202.8M | $433.5M | ||
| Q4 24 | $193.1M | $429.5M | ||
| Q3 24 | $181.0M | $423.1M | ||
| Q2 24 | $168.0M | $418.4M | ||
| Q1 24 | $155.7M | $412.0M |
总资产MDXGRMAX
| Q4 25 | $342.7M | $582.5M | ||
| Q3 25 | $319.0M | $582.2M | ||
| Q2 25 | $291.1M | $574.8M | ||
| Q1 25 | $270.4M | $571.4M | ||
| Q4 24 | $263.9M | $581.6M | ||
| Q3 24 | $243.9M | $578.6M | ||
| Q2 24 | $230.2M | $571.4M | ||
| Q1 24 | $221.7M | $566.7M |
负债/权益比MDXGRMAX
| Q4 25 | 0.07× | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | 0.10× | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.0M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | — | $33.5M |
| 自由现金流率自由现金流/营收 | — | 47.1% |
| 资本支出强度资本支出/营收 | — | 10.4% |
| 现金转化率经营现金流/净利润 | 1.64× | 28.39× |
| 过去12个月自由现金流最近4个季度 | — | $56.8M |
8季度趋势，按日历期对齐
经营现金流MDXGRMAX
| Q4 25 | $25.0M | $40.9M | ||
| Q3 25 | $29.3M | $17.7M | ||
| Q2 25 | $14.4M | $4.6M | ||
| Q1 25 | $5.3M | $5.7M | ||
| Q4 24 | $18.8M | $59.7M | ||
| Q3 24 | $19.6M | $17.6M | ||
| Q2 24 | $21.8M | $15.9M | ||
| Q1 24 | $6.0M | $9.4M |
自由现金流MDXGRMAX
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率MDXGRMAX
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度MDXGRMAX
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 3.3% |
现金转化率MDXGRMAX
| Q4 25 | 1.64× | 28.39× | ||
| Q3 25 | 1.75× | 4.45× | ||
| Q2 25 | 1.50× | 0.97× | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 2.53× | 10.28× | ||
| Q3 24 | 2.42× | 18.22× | ||
| Q2 24 | 1.24× | 4.29× | ||
| Q1 24 | 0.65× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDXG
| Wound | $78.7M | 67% |
| Surgical | $39.4M | 33% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
